Références Scientifiques

Consultez la littérature scientifique qui soutient nos cibles moléculaires et notre approche létale synthétique.

mai 2024

Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib

mai 2024

ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)

janvier 2024

Detection and characterization of DDR reversion alterations in baseline tissue and plasma samples from patients enrolled in the TRESR and ATTACC Phase I clinical trials

octobre 2023

KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition

octobre 2023

Preclinical development of PKMYT1 and ATR inhibitor combinations

Notre pipeline comprend plusieurs programmes de développement.